https://www.statnews.com/2020/04/17/video-chat-what-we-know-about-gileads-remdesivir-data/?
STAT Plus video chat: What we know about Gilead’s remdesivir data
By ADAM FEUERSTEIN @adamfeuerstein and MATTHEW HERPER @matthewherper
APRIL 17, 2020
STAT reported Thursday that a Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week.
- What does this early peek at the data tell us?
- What does it not tell us?
- And what comes next with clinical trials of remdesivir?
STAT senior writer Adam Feuerstein and Matthew Herper brief you on what’s known so far, and take questions from STAT Plus subscribers, in a live video chat.
The live chat will stream below starting at 1 p.m. ET on Friday, April 17.
_____________________
**Comment**
Interestingly, China wants a national patent on it. This would mean if granted, they would exclusively control the drug. Chinese authorities state they won’t seek a “compulsory license,” which means nations can override the patent in national emergencies. This is frightening.
https://www.youtube.com/watch?v=5FDcHHjHx7Q&feature=share&fbclid=IwAR2le904L_oXSW0zxK8V_SSB-5OKf08Jbxr79wxnG4LcqA3OqCf_ayk0fzM Video here, Approx. 1 Min.
